SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

Core Insights - SINTX Technologies has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, enhancing its product portfolio in the foot and ankle fusion market [1][2] - The acquisition includes all intellectual property and product designs related to six differentiated foot and ankle implant systems, which are expected to accelerate commercial launch activities [2][3] - The global ankle fusion market is valued at approximately $750.5 million and is projected to grow to $1.38 billion by 2032, with a CAGR of 9.1% [2] Company Strategy - The acquisition is seen as transformative for SINTX, shifting the focus from R&D to revenue generation and commercial scale [3] - Key members of the SiNAPTIC executive team will join SINTX, bringing expertise in product development, regulatory strategy, and commercialization [3][4] - SINTX will manufacture all devices under its FDA-registered and ISO-certified quality system, leveraging existing FDA clearances to streamline regulatory approvals [4] Financial Details - SINTX issued $750,000 in common shares at a price of $3.465 per share, representing a 10% premium to the closing price on June 20, 2025, along with performance-based common stock purchase warrants [3] - The warrants are exercisable over five years at a strike price of $6.30, vesting upon achieving specific regulatory and commercial milestones [3] Market Position - The acquisition reflects a shared belief in the potential of silicon nitride ceramic-enhanced implants, aiming to accelerate the development of disruptive products [5] - SINTX has been a leader in the research and development of silicon nitride, with products implanted in humans since 2008 [6]